Tango Therapeutics, Inc. Operating Lease Liability
Tango Therapeutics, Inc. (TNGX) had Operating Lease Liability of $33.57 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-03-05
- 2025-12-31: Operating Lease, Liability $33.57M.
- 2023-12-31: Operating Lease, Liability $36.49M; Operating Lease, Liability as first filed $38.92M.
- 2022-12-31: Operating Lease, Liability $41.13M.
- 2021-12-31: Operating Lease, Liability $1.50M.
| Period end | Operating Lease, Liability | Operating Lease, Liability as first filed |
|---|---|---|
| 2025-12-31 | $33.57M 10-K · filed 2026-03-05 | |
| 2023-12-31 | $36.49M 10-K · filed 2025-02-27 | $38.92M 10-K · filed 2024-03-18 |
| 2022-12-31 | $41.13M 10-K · filed 2023-03-27 | |
| 2021-12-31 | $1.50M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |